POSTECH ACADEMY-INDUSTRY FOUNDATION;포항공과대학교 산학협력단;주식회사 엠디헬스케어;MD HEALTHCARE INC.
发明人:
KIM, YOON KEUN,김윤근,BAN, CHANG ILL,반창일,JEON, JIN SEONG,전진성,KIM, YOON KEUNKR,BAN, CHANG ILLKR,JEON, JIN SEONGKR
申请号：
KR1020170081782
公开号：
KR1020180006303A
申请日:
2017.06.28
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
The present invention relates to vesicles derived from bacteria of the genus Propionibacterium and a use thereof. According to the present invention, it was experimentally confirmed that the production of vesicles derived from bacteria of the genus Propionibacterium was increased in the body by a high-fat diet rather than a high-carbohydrate diet； the vesicles were significantly reduced in the blood of patients with cancers, such as breast cancer and liver cancer, inflammation diseases, such as asthma and atopic dermatitis, and metabolic diseases, such as diabetes and liver cirrhosis, compared with normal persons； and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, inhibited the apoptosis of keratinocytes, and increased the expression of an androgen receptor in the body. Thus, the vesicles derived from bacteria of the genus Propionibacterium according to the present invention are expected to be beneficially used in a method for diagnosis or prediction of cancers, inflammatory diseases, endocrine diseases, or metabolic diseases, a pharmaceutical composition, a food product, a cosmetic product, and the like.본 발명은 프로피오니박테리움 속 세균 유래 소포 및 이의 용도에 관한 것으로 고탄수화물식이에 비해 고지방식이에 의해 체내에서 프로피오니박테리움 속 세균 유래 소포 생성이 증가하고, 정상인에 비하여 유방암, 간암 등의 암환자, 천식, 아토피피부염 등의 염증질환, 및 당뇨병, 간경화증 등의 대사질환 환자의 혈액에 상기 소포가 유의하게 감소되어 있고, 상기 소포는 병원성 소포에 의한 염증매개체 분비를 억제함과 동시에 각질세포의 사멸을 억제하고, 체내에서 안드로젠 수용체의 발현을 증가시킴을 실험적으로 확인하였는바, 본 발명에 따른 프로피오니박테리움 속 세균 유래 소포는 암, 염증질환, 내분비질환, 또는 대사질환의 진단 또는 예측방법, 약학적 조성물, 식품, 및 화장품 등에 유용하게 이용될 수 있을 것으로 기대된다.
